{
    "clinical_study": {
        "@rank": "55367", 
        "arm_group": {
            "arm_group_label": "Parkinson's disease", 
            "description": "Patients diagnosed with Parkinson's disease with remaining disabling motor complications despite optimized per-oral or other treatment regimens suitable for Levodopa Carbidopa Intestinal Gel treatment in accordance with the Swedish Summary of Products Characteristics"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the use of resources, measured as number of\n      contacts and time spent by the Duodopa Nurse Specialist, the Investigator, and the\n      telemedicine Technician, during titration of Levodopa Carbodopa Intestinal Gel at home using\n      Telemedicine."
        }, 
        "brief_title": "Levodopa Carbidopa Intestinal Gel Home Titration Using Telemedicine: Evaluation of Use of Resources", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Suitable for Levodopa Carbidopa Intestinal Gel treatment in accordance with the\n             Swedish Summary of Product Characteristics\n\n          -  >18 years of age\n\n          -  Motivated and confident to test Levodopa Carbidopa Intestinal Gel home titration by\n             using Telemedicine\n\n          -  Able to handle the infusion pump and the Telemedicine equipment by themselves or with\n             assistance, as determined by the Investigator.\n\n          -  Able to understand and sign the study informed consent form\n\n        Exclusion Criteria:\n\n          -  Dementia or cognitive decline with Mini Mental State Examination score < 24\n\n          -  Ongoing symptomatic depression, hallucinations or other psychotic behaviors without\n             adequate treatment, as determined by the Investigator.\n\n          -  Contraindications as described in the Swedish Summary of Product Characteristics:\n             Hypersensitivity to levodopa or carbidopa, Narrow angle glaucoma, Serious liver and\n             kidney disease, Severe heart failure, Acute myocardial infarction, Severe cardiac\n             arrhythmias, Recent or acute stroke, Contraindications for adrenergic effects;\n             pheochromocytoma, hyperthyroidism, Cushing's syndrome, Other contraindications for\n             abdominal surgery.\n\n          -  Any other reasons making the patient unsuitable for home titration using\n             Telemedicine, as determined by the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients admitted to motor disorder speciality clinics."
            }
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956032", 
            "org_study_id": "P14-000"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carbidopa", 
                "Levodopa", 
                "Carbidopa, levodopa drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "LCIG", 
            "Parkinson's disease", 
            "levodopa carbidopa intestinal gel", 
            "Telemedicine"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "link": {
            "url": "http://rxabbvie.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Linkoping", 
                        "country": "Sweden", 
                        "zip": "581 85"
                    }, 
                    "name": "Site Reference ID/Investigator# 96718"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 96718", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden", 
                        "zip": "22185"
                    }, 
                    "name": "Site Reference ID/Investigator# 96720"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 96720", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "141 86"
                    }, 
                    "name": "Site Reference ID/Investigator# 96721"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 96721", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uppsala", 
                        "country": "Sweden", 
                        "zip": "SE 75185"
                    }, 
                    "name": "Site Reference ID/Investigator# 96719"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 96719", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_groups": "1", 
        "official_title": "Levodopa Carbidopa Intestinal Gel Home Titration Using Telemedicine: Evaluation of Use of Resources", 
        "overall_contact": {
            "email": "anna.urbom@abbvie.com", 
            "last_name": "Anna  Urbom, BS", 
            "phone": "+46 70 16 80 818"
        }, 
        "overall_contact_backup": {
            "email": "ewa.berndtson@abbvie.com", 
            "last_name": "Ewa  Berndtson", 
            "phone": "+46 70 337 43 73"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Eva  Dahl, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Resource use is composed of the health care professional and technician time in hours used during the study period. Health care professional-time is defined as Duodopa Nurse Specialist- and Investigator time, in contact with patient by visiting the patient's home, by telemedicine equipment or by telephone. Telemedicine technician time will include time for telemedicine equipment setup, demounting and adjustments if needed.", 
            "measure": "Resource use", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956032"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total time for titration period is defined as the time in hours from start of the pump and Levodopa Carbidopa Intestinal Gel delivery via the naso-jejunal tube, to the decision of a permanent Percutaneous Endoscopic Gastrojejunostomy surgery or termination of Levodopa Carbidopa Intestinal Gel treatment.", 
                "measure": "Total time for titration", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Patents daily free time is a maximum 24 hours, and is defined as time spent on activities (e.g. work, household, chores, leisure time, travel, sleep etc.) other than time spent on health care professional-communication, dose adjustments and pump handling.", 
                "measure": "Patient's daily free time", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Telemedicine equipment mishandling, intentional misuse, technical problems", 
                "measure": "Technical feasibility", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Other health care contacts related to Parkinson's Disease not scheduled within the telemedicine care chain", 
                "measure": "Health care utilization", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Clinical Global Impression - Improvement will be used to document the Investigator's impression of the patients improvement from decision to start Levodopa Carbidopa Intestinal Geltitration (baseline) to decision on Percutaneous Endoscopic Gastrojejunostomy-surgery.", 
                "measure": "Clinical Global Impression - Improvement", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Experience of Levodopa Carbidopa Intestinal Gel home titration using Telemedicine will be collected through semi-structured interviews with the patient and caregiver.", 
                "measure": "Experience of Levodopa Carbidopa Intestinal Gelhome titration using Telemedicine", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}